Efficient delivery of T cell epitopes to APC by use of MHC class II-specific troybodies

被引:39
作者
Lunde, E
Western, KH
Rasmussen, IB
Sandlie, I
Bogen, B
机构
[1] Univ Oslo, Dept Biol, Div Mol Cell Biol, N-0316 Oslo, Norway
[2] Univ Oslo, Natl Hosp, Inst Immunol, Oslo, Norway
关键词
D O I
10.4049/jimmunol.168.5.2154
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A major objective in vaccine development is the design of reagents that give strong, specific T cell responses. We have constructed a series of rAb with specificity for MHC class II (I-E). Each has one of four different class H-restricted T cell epitopes genetically introduced into the first C domain of the H chain. These four epitopes are: 91-101 lambda2(315), which is presented by I-E-d; 110-120 hemagglutinin (I-E-d); 323-339 OVA (I-A(d)); and 46-61 hen egg lysozyme (I-A(k)). We denote such APC-specific, epitope-containing Ab "Troybodies." When mixed with APC, all four class II-specific Troybodies were similar to1,000 times more efficient at inducing specific T cell activation in vitro compared with nontargeting peptide Ab. Furthermore, they were 1,000-10,000 times more efficient than synthetic peptide or native protein. Conventional intracellular processing of the Troybodies was required to load the epitopes onto MHC class H. Different types of professional APC, such as purified B cells, dendritic cells, and macrophages, were equally efficient at processing and presenting the Troybodies. In vivo, class H-specific Troybodies were at least 100 times more efficient at targeting APC and activating TCR-transgenic T cells than were the nontargeting peptide Ab. Furthermore, they were 100-100,000 times more efficient than synthetic peptide or native protein. The study shows that class H-specific Troybodies can deliver a variety of T cell epitopes to professional APC for efficient presentation, in vitro as well as in vivo. Thus, Troybodies may be useful as tools in vaccine development.
引用
收藏
页码:2154 / 2162
页数:9
相关论文
共 54 条
[1]  
ALLEN PM, 1984, J IMMUNOL, V132, P1077
[2]   PROCESSING OF LYSOZYME BY MACROPHAGES - IDENTIFICATION OF THE DETERMINANT RECOGNIZED BY 2 T-CELL HYBRIDOMAS [J].
ALLEN, PM ;
STRYDOM, DJ ;
UNANUE, ER .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1984, 81 (08) :2489-2493
[3]   ANTIGEN PRESENTATION BY RESTING B-CELLS RADIOSENSITIVITY OF THE ANTIGEN-PRESENTATION FUNCTION AND 2 DISTINCT PATHWAYS OF T-CELL ACTIVATION [J].
ASHWELL, JD ;
DEFRANCO, AL ;
PAUL, WE ;
SCHWARTZ, RH .
JOURNAL OF EXPERIMENTAL MEDICINE, 1984, 159 (03) :881-905
[4]   IMMUNOGENIC TARGETING OF RECOMBINANT PEPTIDE VACCINES TO HUMAN ANTIGEN-PRESENTING CELLS BY CHIMERIC ANTI-HLA-DR AND ANTISURFACE IMMUNOGLOBULIN-D ANTIBODY FAB FRAGMENTS IN-VITRO [J].
BAIER, G ;
BAIERBITTERLICH, G ;
LOONEY, DJ ;
ALTMAN, A .
JOURNAL OF VIROLOGY, 1995, 69 (04) :2357-2365
[5]  
Baiu DC, 1999, J IMMUNOL, V162, P3125
[6]   Dendritic cells and the control of immunity [J].
Banchereau, J ;
Steinman, RM .
NATURE, 1998, 392 (6673) :245-252
[7]  
BIKOFF E, 1986, J IMMUNOL, V137, P28
[8]   MINIMUM LENGTH OF AN IDIOTYPIC PEPTIDE AND A MODEL FOR ITS BINDING TO A MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-II MOLECULE [J].
BOGEN, B ;
LAMBRIS, JD .
EMBO JOURNAL, 1989, 8 (07) :1947-1952
[9]   A STIMULATORY MONOCLONAL-ANTIBODY DETECTING T-CELL RECEPTOR DIVERSITY AMONG IDIOTYPE-SPECIFIC, MAJOR HISTOCOMPATIBILITY COMPLEX-RESTRICTED T-CELL CLONES [J].
BOGEN, B ;
LAURITZSEN, GF ;
WEISS, S .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1990, 20 (10) :2359-2362
[10]   NAIVE CD4(+) T-CELLS CONFER IDIOTYPE-SPECIFIC TUMOR RESISTANCE IN THE ABSENCE OF ANTIBODIES [J].
BOGEN, B ;
MUNTHE, L ;
SOLLIEN, A ;
HOFGAARD, P ;
OMHOLT, H ;
DAGNAES, F ;
DEMBIC, Z ;
LAURITZSEN, GF .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1995, 25 (11) :3079-3086